Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CJRB 102

Next Previous
Drug Profile

CJRB 102

Alternative Names: CJRB-102; MRx-0518; MRx-518

Latest Information Update: 15 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4D Pharma PLC
  • Developer 4D Pharma PLC; Imperial College of Science, Technology and Medicine; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; NF-kappa B modulators; Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Pancreatic cancer
  • Preclinical Breast cancer

Most Recent Events

  • 08 May 2023 4D Pharma terminates a phase I trial in Pancreatic cancer (Monotherapy) in USA (PO) due to sponsor insolvency (PO, Capsule) (NCT04193904)
  • 08 May 2023 4D pharma and Merck terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in USA (PO) due to sponsor insolvency (NCT03637803)
  • 18 Apr 2023 4D pharma withdraws the phase II AVENU trial in Urogenital cancer (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable, Second line therapy or greater) in USA (PO), as the sponsor unable to proceed (NCT05107427)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top